INTRODUCTION
============

PLA~2~ (phospholipase A~2~) enzymes catalyse the hydrolysis of the *sn*-2 position of glycerophospholipids to give rise to fatty acids and lysophospholipids. They are subdivided into several groups: high-molecular-mass intracellular PLA~2~s with a catalytic serine residue, including cPLA~2~ (cytosolic PLA~2~) and iPLA~2~ (Ca^2+^-independent PLA~2~) enzymes, and low-molecular-mass disulfide-rich Ca^2+^-dependent sPLA~2~ (secretory PLA~2~) family with a catalytic histidine residue. To date, ten catalytically active sPLA~2~ enzymes have been identified in mammals (IB, IIA, IIC, IID, IIE, IIF, III, V, X and XIIA). On a structural basis, these enzymes are subdivided further into three branches, namely group I/II/V/X, group III and group XII \[[@B1]--[@B3]\]. Individual sPLA~2~s exhibit unique tissue and cellular localizations and enzymatic properties, suggesting their distinct tissue-specific roles in various pathophysiological events.

Because group IIA sPLA~2~ (PLA2G2A; or synovial sPLA~2~) is strongly induced during inflammatory conditions such as rheumatoid arthritis or sepsis and because sPLA~2~s from snake or bee venom can elicit inflammation when administered *in vivo*, it has long been thought that sPLA~2~ contributes to inflammation, probably by augmenting the generation of pro-inflammatory lipid mediators \[[@B1]--[@B3]\]. However, Tg (transgenic) mice overexpressing PLA2G2A do not show any sign of inflammation, even though they have alopecic skin \[[@B4]\], raising the question as to whether this sPLA~2~ actually exerts a pro-inflammatory role *in vivo*. Although recent gene targeting studies of new members of the sPLA~2~ family, group V (PLA2G5) and group X (PLA2G10), have provided several lines of evidence that they participate in some types of inflammation \[[@B5]--[@B8]\], general understanding of the roles played by sPLA~2~s in the onset of inflammation, including their modes of action, is still incomplete and needs further clarification. Nonetheless, Tg strategies are still likely to provide some functional and mechanistic insights into the *in vivo* actions of sPLA~2~s, as knowledge of the antibacterial and pro-atherogenic properties of sPLA~2~s has been advanced by studies using *Pla2g2a*-Tg mice \[[@B9],[@B10]\]. However, the early mortality of *Pla2g5*-Tg mice \[[@B11]\] and macrophage-specific *Pla2g10*-Tg mice \[[@B12]\] due to lung injury probably resulting from aberrant surfactant degradation limits their subsequent use. So far, there has been no sPLA~2~-Tg mouse model that spontaneously develops systemic inflammation.

Group III sPLA~2~ (PLA2G3) is unique in that it consists of a central sPLA~2~ (S) domain, which is homologous with bee venom sPLA~2~ rather than with other mammalian sPLA~2~s, flanked by distinctive N- and C-terminal domains \[[@B13]\]. Forced expression of PLA2G3 or its central S domain alone in several cell types results in increased arachidonic acid metabolism, for which its potency is superior to that of PLA2G2A and next to that of PLA2G10 and PLA2G5 \[[@B14],[@B15]\]. In an effort to elucidate the functions of PLA2G3 *in vivo*, we have recently generated Tg mice expressing human PLA2G3 in all tissues under the control of the CAG (chicken β-actin) promoter. An initial study of *Pla2g3*-Tg mice provided the novel information that PLA2G3 can hydrolyse PC (phosphatidylcholine) in plasma lipoproteins to facilitate macrophage foam cell formation *ex vivo* and atherosclerosis *in vivo* \[[@B16]\]. In the present study, we have demonstrated another aspect of *Pla2g3*-Tg mice in that they spontaneously develop inflammation in multiple organs as they age. This mouse model will therefore be useful for analysing and understanding the molecular events in inflammation caused by increased expression of sPLA~2~.

MATERIALS AND METHODS
=====================

Animals
-------

All mice were housed in climate-controlled (21 °C) specific pathogen-free facilities with a 12 h light/12 h dark cycle, with free access to standard laboratory food (Picolab mouse diet 20; Laboratory Diet) and water. All procedures involving animals were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Showa University, in accordance with the Standards Relating to the Care and Management of Experimental Animals in Japan. The generation of *Pla2g3*-Tg mice has been reported previously \[[@B16]\].

RT (reverse transcription)--PCR
-------------------------------

Total RNA was extracted from mouse tissues with TRIzol® reagent (Invitrogen). For RT--PCR, first-strand cDNA synthesis was carried out using SuperScript III reverse transcriptase kit (Invitrogen). Total RNA (5 μg) was used in reactions primed with oligo(dT) (12--18-mer) primer (Invitrogen) to obtain cDNA. Then, 1 μl of the synthesized cDNA was used as the template for the mRNA-amplification reactions. The PCR amplification was performed on a GeneAmp9600 PCR system (PerkinElmer) with an ExTaq kit (TaKaRa Bio). The primers used are as follows: 5′-GAAAGCATGATCCGCGACGTGGAA-3′ and 5′-CCCTTCTCCAGCTGGAAGACTCCT-3′ for mouse TNFα (tumour necrosis factor α); 5′-AGGGCTGCTTCCAAACCTTTGACC-3′ and 5′-CCAGTTGGGGAACTCTGCAGACTC-3′ for mouse IL (interleukin)-1β; 5′-CAGAGGATACCACTCCCAACAGAC-3′ and 5′-CCTTAGCCACTCCTTCTGTGACTC-3′ for mouse IL-6; 5′-CAGCTAGTTGTCATCCTGCTCTTC-3′ and 5′-GGTGCAGCTTATCGATGAATCCAG-3′ for mouse IL-4; 5′-GCTACACACTGCATCTTGGCTTTG-3′ and 5′-GTGGGTTGTTGACCTCAAACTTGG-3′ for mouse IFNγ (interferon γ); 5′-CGTGCACTGAGGCTCACAAATGTTTC-3′ and 5′-TTTCTTGCACCAGCCATGAGC-3′ for mouse IL-12 p40 subunit; 5′-CATGCTTCTGGGCCTGCTGTTC-3′ and 5′-CAGAAGTGCTTGAGGTGGTTGTGG-3′ for mouse CCL2/MCP-1 (monocyte chemoattractant protein-1); 5′-AAGGGGCCCAAGATCCGCTACA-3′ and 5′-GTAGACCCTGCGCTTCTCGTTCCA-3′ for mouse CXCL14/BRAK (breast- and kidney-expressed chemokine); 5′-GAGCACTGGCCACTCTTCAGAGTCAG-3′ and 5′-CGAGGAGTTCCCAGCAGAATCTCCAA-3′ for human PLA2G3; 5′-GGCTGAGGCCACCTCATATACTTC-3′ and 5′-TCCTTTGCCCTCAGCACAGTCAAG-3′ for mouse PLA2G3; 5′-GGTCTCCTCACACTGGCTTGGTTC-3′ and 5′-CAGTAGACCAGCTTCCGGTCACAG-3′ for mouse PLA2G5; 5′-GACCCGGATTCAGCGAAGCAACCA-3′ and 5′-CAGCTCCTCGTCACACCTGCACAA-3′ for mouse PLA2G10; 5′-GCTGGCCGGTATAACTGCAA-3′ and 5′-ACACAGTTGCCTTTCACACCA-3′ for mouse PLA2G2D; 5′-ACCTCCCATTGCCCTGGCTT-3′ and 5′- GGCCCAGTACACAGCTTGTTGG-3′ for mouse PLA2G2E; 5′-GGTTAAACACTCCACTGGACGGAA-3′ and 5′-CTCGGTACTTGTTCCTGTATGGGT-3′ for mouse PLA2G2F; 5′-CGCTCCATTAAGCTGTGGTTTGTGATTCGG-3′ and 5′-AGACTGGCTCCTGGCTGCTTGATGATCTTC-3′ for mouse HDC (histidine decarboxylase); 5′-ACCACATTCTCGCCCTTACAT-3′ and 5′-TCTCAGTTTCACCTCCCTCAG-3′ for mMCP (mouse mast cell protease)-4; 5′-ATAACAGTCCTCCTAGGAGCC-3′ and 5′-GATCCAGGGCCTGTAATGGGA-3′ for mMCP-5; 5′-GCACATCAAAAGCCCACAGC-3′ and 5′-TAGACAGGGGAGACAGAGGAC-3′ for mMCP-6; and 5′-TCGTGGATCTGACGTGCCGCCTG-3′ and 5′-CACCACCCTGTTGCTGTAGCCGTAT-3′ for mouse GAPDH (glyceraldehyde-3-phosphate dehydrogenase). The PCR products were analysed on a 1.5% agarose gel and visualized using ethidium bromide staining.

Quantitative RT--PCR
--------------------

For quantitative RT--PCR, cDNA synthesis was performed using the high-capacity cDNA reverse transcription kit (Applied Biosystems). The reaction was carried out on an ABI Prism 7000 sequence detection system (Applied Biosystems) with TaqMan gene expression master mix (Applied Biosystems). Pre-designed TaqMan assays (Applied Biosystems) were used to determine gene expression: Mm00839636 for mouse CD68, Mm00478374 and Mm00478374 for mouse COX (cyclo-oxygenase)-1 and -2 respectively, Mm00447040 for mouse cPLA~2~α, and Mm00452105 and Mm00460181 for mouse mPGES (microsomal prostaglandin E synthase)-1 and -2 respectively.

Histochemistry
--------------

Formalin-fixed tissues were embedded in paraffin, sectioned, mounted on glass slides, deparaffinized in xylene and rehydrated in ethanol with increasing concentrations of water. The cell type was identified from conventional haematoxylin and eosin staining. For PAS (periodic acid--Schiff) staining, tissue sections were deparaffinized, rehydrated and placed in 0.5% periodic acid solution for 5 min. After washing in water, the sections were placed in Coleman\'s Schiff reagent for 15 min, washed in water for 10 min and counterstained with haematoxylin solution for 15 min. After washing in water for 15 min, the sections were dehydrated and mounted with resinous medium.

Measurement of eicosanoids
--------------------------

The contents of PGE~2~ (prostaglandin E~2~) and LTB~4~ (leukotriene B~4~) in mouse skins were quantified using PGE~2~ and LTB~4~ enzyme immunoassay kits (Cayman Chemicals).

Measurement of MPO (myeloperoxidase) activity
---------------------------------------------

The tissue samples were homogenized in 50 mM potassium phosphate buffer (pH 6.0) containing 1% (w/v) hexadecyltrimethylammonium bromide and centrifuged at 12000 ***g*** for 15 min at 4 °C. An aliquot (30 μl) was added to 180 μl of the buffer containing 0.167 mg/ml *o*-dianisidine dihydrochloride and 0.0005% (v/v) hydrogen peroxidase (Sigma--Aldrich). After appropriate periods of incubation at 37 °C, the absorbance at 460 nm was measured. MPO activity was calculated using a standard curve generated with human MPO (Sigma), and values were normalized to protein concentration.

Determination of cell types in blood circulation
------------------------------------------------

Blood was collected from mouse tail biopsy with 10 mM EDTA as an anticoagulant. The blood samples were applied to a clinical blood cell analyser VetScan HM (Abaxis) to determine the numbers of lymphocytes, granulocytes, monocytes, erythrocytes and platelets, the haemoglobin content and the haematocrit value.

Flow cytometry (FACS)
---------------------

Suspensions of 10^6^ splenic cells were treated on ice with anti-\[mouse CD16/CD32 (FcγRII/RIII)\] monoclonal antibody (BD Biosciences) to block cell-surface Fcγ receptors. Then the cells were incubated with FITC-, phycoerythrin- or Alexa Fluor® 488-labelled monoclonal antibodies against mouse CD3, CD4, CD8, CD11b (Mac1), CD11c, CD21, CD23, CD45R, Gr-1, NK1.1, sIgD and sIgM (BD Biosciences). Flow cytometric analysis was carried out on a FACS Aria cell-sorting system (BD Biosciences).

ESI (electrospray ionization)--MS
---------------------------------

Lungs of mice were lavaged with 1 ml of SET buffer (250 mM sucrose, 0.5 mM EDTA and 20 mM Tris/HCl, pH 7.4), and the resulting bronchoalveolar lavage fluid was used after centrifugation at 160 ***g*** for 10 min at 4 °C to remove the cells and tissue debris. Lipids were extracted from the bronchoalveolar lavage fluid using the method of Bligh and Dyer \[[@B16a]\]. PC with C~14:1~--C~14:1~ (diacyl) was added to the samples (1 nmol of internal standard per 1 mg of protein equivalents) as an internal standard. MS spectra were obtained on a Quattro Micro tandem quadrupole mass spectrometer (Micromass) equipped with ESI, as described previously \[[@B11]\]. Lipid extracts were reconstituted in 2:1 chloroform/methanol (100--300 μmol of phosphorus/l), and 2 μl of the sample was injected per run. The samples were introduced by means of a flow injector into the ESI chamber at a flow rate of 4 μl/min in a solvent system of acetonitrile/methanol/water (2:3:1, by vol.) containing 0.1% (v/v) ammonium formate (pH 6.4). The mass spectrometer was operated in the positive- and negative-scan modes. The flow rate of the nitrogen drying gas was 12 l/min at 80 °C. The capillary and cone voltages were set at 3.7 kV and 30 V respectively, argon at (3--4)×10^4^ Torr (1 Torr=133.3 Pa) was used as the collision gas, and a collision energy of 30--40 V was used for obtaining fragment ions for precursor ions.

Determination of serum immunogloblin levels
-------------------------------------------

Serum titres of IgM, IgG~1~, IgG~2~ and IgE were determined using a mouse IgX ELISA quantification kit (Bethyl Laboratories).

RESULTS
=======

*Pla2g3*-Tg mice develop dermatitis
-----------------------------------

*Pla2g3*-Tg mice appeared normal at birth and showed no apparent abnormality up to 9 months of age under our housing conditions (except that the Tg mice had altered plasma lipoproteins, as described in \[[@B16]\]). Subsequently, however, we noted that about one-third of PLA2G3 mice, both male and female, experienced gradual hair loss on their facial, neck and dorsal skin, which subsequently (typically within 2--3 months) developed into focally alopecic lesions that were often filled with pus ([Figure 1](#F1){ref-type="fig"}A). Behaviour suggestive of increasing itching eventually worsened the lesions further. Neither age-matched non-Tg WT (wild-type) mice nor Tg mice expressing LNL (LoxP--neomycin-resistance gene--LoxP)--PLA2G3 (i.e. mice harbouring the PLA2G3 transgene in a silent state \[[@B16]\]) exhibited these skin abnormalities ([Figure 1](#F1){ref-type="fig"}A), implying that the phenotype resulted from Tg overexpression of PLA2G3. Subsequent studies mostly focused on aged (9--12 months) PLA2G3 mice that developed dermatitis, with age-matched WT mice as controls.

![Histology of dermatitis in aged *Pla2g3*-Tg mice\
(**A**) Appearance of 1-year-old WT (panel a), *LNL*--*Pla2g3*-Tg (LNL-III-Tg) (panel b) and *CAG*--*Pla2g3*-Tg (III-Tg) (panels c and d) mice. Whereas WT and LNL--*Pla2g3*-Tg mice were grossly normal, *CAG*--*Pla2g3*-Tg mice frequently developed lesion areas on facial, neck and back skins (red arrows). (**B**) Skin histology of WT and *Pla2g3*-Tg mice. In contrast with the normal appearance of the skins of WT mice (panel a), those of *Pla2g3*-Tg mice showed multiple abnormalities (panels b--i) that are similar to those seen in psoriasis and atopic dermatitis in humans. Typically, the Tg skins exhibit hyperkeratosis (dark arrows; panels b, c and g) with thickened cornified layers (blue arrows; panels c and g), acanthosis (yellow arrows; panel c) and parakeratosis (open green arrows; panels c--e). Sebaceous glands (green arrows) are hyperplasic and hair shafts (broken arrows) were bent over within hair follicles in *Pla2g3*-Tg mice (panel b) compared with normal appearance of those in control mice (panel a). Epidermis was focally lost, where erosion and ulcer (stars) were found in the Tg mice (panels d, e, g and h). Boxed areas in panels d and g are magnified in panels e and h respectively. A lot of inflammatory cell infiltrates were found in the dermis of the Tg mice (green asterisks, panels c--h). A magnified vision of the Tg dermis demonstrates the accumulation of polymorph nuclear neutrophils and flat-shaped mononuclear macrophages, as exemplified by light blue arrows and red arrows respectively in panel i.](bic657i001){#F1}

Histological examination revealed many abnormalities in the skin of *Pla2g3*-Tg mice ([Figure 1](#F1){ref-type="fig"}B, panels b--i) as compared with the normal appearance of the skin of WT mice ([Figure 1](#F1){ref-type="fig"}B, panel a). *Pla2g3*-Tg mice (1-year-old) showed dense cellularity in the dermis with markedly increased numbers of haematoxylin-stained nuclei, which were mostly ascribed to infiltrating polymorphonuclear neutrophils and macrophages ([Figure 1](#F1){ref-type="fig"}B, panels b--i). *Pla2g3*-Tg mice had thickened epidermis (acanthosis) with dense cornified layers, sebaceous gland hyperplasia and epidermal rete peg formation (downward papillary projection of the epidermis) ([Figure 1](#F1){ref-type="fig"}B, panels b and c). In contrast with hair shafts that emerged straight out of the hair canals in WT mice ([Figure 1](#F1){ref-type="fig"}B, panel a), those in *Pla2g3*-Tg mice often bent over within the canals, probably because highly thickened interfollicular and follicular keratinocyte layers prevented the protrusion of the hair shafts ([Figure 1](#F1){ref-type="fig"}B, panel b). Parakeratosis, which represents unusual retention of nuclei in the outermost cornified layers, was frequently observed in severe lesions in *Pla2g3*-Tg mice ([Figure 1](#F1){ref-type="fig"}B, panels c--e), where the epidermis was focally lost resulting in cutaneous erosion and ulcers with massive neutrophil infiltration ([Figure 1](#F1){ref-type="fig"}B, panels d, e, g and h).

RT--PCR showed that pro-inflammatory cytokines, including TNFα, IL-1β and IL-6, and CCL2/MCP-1 were highly expressed in the inflamed skin lesions of *Pla2g3*-Tg mice, but not in control mice ([Figure 2](#F2){ref-type="fig"}A). CXCL14 (BRAK), a skin chemokine, was faintly detected in WT skin and was also increased in Tg skin. The T~H2~ cytokine IL-4 was weakly, but significantly, detected in Tg, but not WT, skin, whereas the T~H1~ cytokines IFNγ and IL-12 were below the detection limit in both genotypes ([Figure 2](#F2){ref-type="fig"}A). Moreover, MPO activity, which mirrors neutrophil infiltration, in skin sections was markedly elevated in *Pla2g3*-Tg mice compared with WT mice ([Figure 2](#F2){ref-type="fig"}B). Quantitative RT--PCR demonstrated a marked increase in CD68, a macrophage marker, in *Pla2g3*-Tg skin relative to WT skin ([Figure 2](#F2){ref-type="fig"}C), consistent with macrophage infiltration. In contrast, the expression levels of mast cell markers, including mMCP-4, -5 and -6 (mast cell proteases), were unchanged between control and PLA2G3 skin ([Figure 2](#F2){ref-type="fig"}D), indicating that the mast cell population was unaffected by Tg expression of PLA2G3. Therefore increased expression of HDC (a histamine-biosynthetic enzyme) in the Tg skin ([Figure 2](#F2){ref-type="fig"}D) might reflect the increase in macrophages, in which a trace level of HDC is expressed \[[@B17]\], or, alternatively, the expression of HDC, but not mMCPs, in mast cells might be specifically controlled by PLA2G3.

![Increases in expression of cytokines/chemokines and infiltration of neutrophils/macrophages in skin of *Pla2g3*-Tg mice\
(**A**) RNAs prepared from the skin of WT mice (left-hand lanes) and *Pla2g3*-Tg mice (III-Tg; right-hand lanes) were subjected to RT--PCR to assess the expression of pro-inflammatory (TNFα, IL-1β and IL-6), T~H2~ (IL-4) and T~H1~ (IFNγ and IL-12 p40 subunit) cytokines, and chemokines (CCL2 and CXCL14). RT--PCR for GAPDH was also carried out to verify equal loading of samples into each lane. (**B**) MPO activity in homogenates of WT and *Pla2g3*-Tg (III-Tg) skin (means±S.D., *n*=3). (**C**) Expression of CD68, a macrophage marker, in skin from WT mice and *Pla2g3*-Tg mice (III-Tg) was assessed using quantitative RT--PCR (means±S.D., *n*=3). (**D**) Expression of mMCP-4, -5 and -6 (mast cell proteases) and HDC in WT and Tg skin.](bic657i002){#F2}

Furthermore, a marked increase in PGE~2~ was observed in the skin of *Pla2g3*-Tg mice compared with that of WT mice ([Figure 3](#F3){ref-type="fig"}A). Consistent with this, expression of COX-2 and mPGES-1, which are inducible enzymes that act sequentially in the PGE~2~-biosynthetic pathway downstream of PLA~2~ \[[@B18]\], was higher in *Pla2g3*-Tg skin lesions than in WT skin ([Figure 3](#F3){ref-type="fig"}B). In particular, the induction of COX-2 was markedly higher in Tg skin relative to WT skin, whereas cutaneous expression levels of cPLA~2~α, COX-1 and mPGES-2 were similar between the genotypes ([Figure 3](#F3){ref-type="fig"}B). Therefore increased expression of pro-inflammatory cytokines by infiltrating macrophages or hyperplasic epidermal keratinocytes may contribute to the induction of COX-2 and mPGES-1, which in turn leads to increased PGE~2~ synthesis in *Pla2g3*-Tg skin. Although we also measured LTB~4~, a leukotriene produced by neutrophils and macrophages, in skin homogenates as well as serum of *Pla2g3*-Tg mice, it was below the detection limit probably because of its instability.

![Elevations of PGE~2~ and its biosynthetic enzymes in skin of *Pla2g3*-Tg mice\
(**A**) Skin homogenates from WT mice and *Pla2g3*-Tg mice (III-Tg) were subjected to PGE~2~ enzyme immune assay. (**B**) Expression of PGE~2~-biosynthetic enzymes in skins of WT and *Pla2g3*-Tg (III-Tg) mice was assessed by quantitative RT--PCR (means±S.D., *n*=3). The PGE~2~-biosynthetic pathway is indicated. PGH~2~, prostaglandin H~2~. (**C**) Expression of sPLA~2~s in WT and *Pla2g3*-Tg (Tg) skin was assessed by RT--PCR.](bic657i003){#F3}

The expression of various sPLA~2~ enzymes in the skin of WT and Tg mice is shown in [Figure 3](#F3){ref-type="fig"}(C). Interestingly, transcripts of endogenous mouse PLA2G3 were clearly detected in control skin ([Figure 3](#F3){ref-type="fig"}C). To our knowledge, this is the first demonstration that PLA2G3 is intrinsically expressed in mouse skin. Expression of PLA2G2D and PLA2G5 was increased in Tg lesion skin compared with unaffected Tg skin and with WT skin, whereas expression of PLA2G10 was below the detection limit in the skin of both genotypes ([Figure 3](#F3){ref-type="fig"}C). Another intriguing finding is constitutive expression of PLA2G2E and PLA2G2F at relatively high levels in the skin of both genotypes ([Figure 3](#F3){ref-type="fig"}C).

Inflammation in other tissues
-----------------------------

The finding that several inflammatory markers were elevated in the skin lesions of *Pla2g3*-Tg mice ([Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) prompted us to examine whether other tissues in these mice also display inflammatory symptoms. We showed previously that *Pla2g5*-Tg mice die at birth because of lung injury resulting from aberrant hydrolysis of lung surfactant phospholipids, and that the lungs of newborn *Pla2g5*-Tg mice are characterized by abnormally thickened alveolar walls with formation of hyaline membranes lining the alveolar surfaces \[[@B11]\]. In marked contrast, the alveolar architecture of *Pla2g3*-Tg mice was largely indistinguishable from that of age-matched WT mice ([Figure 4](#F4){ref-type="fig"}A, panels a and b). When surfactant lipids were extracted from bronchoalveolar lavage fluid of WT and *Pla2g3*-Tg mice and were subjected to ESI--MS analysis, the composition of the surfactant PC ([Figure 4](#F4){ref-type="fig"}B) and phosphatidylglycerol (results not shown) was similar in WT and *Pla2g3*-Tg mice. However, goblet cell hyperplasia, which was visualized by PAS staining, was evident in the bronchial epithelium of *Pla2g3*-Tg mice compared with WT mice, suggesting increased mucus secretion in the former ([Figure 4](#F4){ref-type="fig"}A, panels c and d). In addition, perivascular lymph aggregates were frequently found in the lungs of *Pla2g3*-Tg mice compared with WT mice ([Figure 4](#F4){ref-type="fig"}A, panels e and f). These observations suggest that PLA2G3 elicits airway inflammation through a mechanism independent of increased lung surfactant hydrolysis.

![Inflammatory symptoms in multiple tissues of *Pla2g3*-Tg mice\
(**A**) Histology of lungs from 1-year-old WT (panels a, c and e) and *Pla2g3*-Tg (III-Tg) mice (panels b, d and f). No overt abnormalities were found in the alveoli of *Pla2g3*-Tg mice (III-Tg; panel b) compared with WT mice (panel c). PAS staining revealed increased goblet cells (green arrows) in the bronchial epithelium of *Pla2g3*-Tg mice (panel d) compared with WT mice (panel c). Perivascular lymph aggregates (blue arrows) were frequently found in the lung of *Pla2g3*-Tg mice (panel f) relative to WT mice (panel e). (**B**) ESI--MS analyses of lung surfactant (PC) prepared from WT mice (upper panel) and *Pla2g3*-Tg mice (III-Tg) (lower panel). Peaks for major PC molecular species and an internal standard (PC with C~14:1~--C~14:1~) are indicated. No abnormality was found in the lung surfactant of *Pla2g3*-Tg mice. I.S., internal standard. (**C**) Histology of salivary glands of 1-year-old WT mice (panel a) and *Pla2g3*-Tg mice (III-Tg; panels b and c). Salivary glands of *Pla2g3*-Tg mice showed glandular swelling (dark arrows) and interstitial lymphocyte infiltration (asterisks). Magnifications, ×200 in panels a and b; ×400 in panel c. (**D**) Histology of livers from 1-year-old WT mice (panel a) and *Pla2g3*-Tg mice (III-Tg; panel b). Extramedullary haemopoiesis was found in the *Pla2g3*-Tg mice (red arrow; panel b). Magnification, ×200.](bic657i004){#F4}

We also found notable inflammatory changes in salivary glands ([Figure 4](#F4){ref-type="fig"}C) and liver ([Figure 4](#F4){ref-type="fig"}D) of *Pla2g3*-Tg mice. Compared with WT mice ([Figure 4](#F4){ref-type="fig"}C, panel a), the salivary glands of *Pla2g3*-Tg mice showed marked glandular swelling accompanied by infiltration of lymphocytes in the interstitium ([Figure 4](#F4){ref-type="fig"}C, panels b and c); this histological feature resembles lymphocytic sialadenitis in humans. In addition, foci of extramedullary haemopoiesis, an event that often occurs during systemic inflammation, were found in the liver of *Pla2g3*-Tg mice ([Figure 4](#F4){ref-type="fig"}D, panel b), whereas they were absent from WT mice ([Figure 4](#F4){ref-type="fig"}D, panel a).

Furthermore, *Pla2g3*-Tg mice, even at 5 months of age at which time no skin inflammation was apparent, frequently showed splenomegaly ([Figure 5](#F5){ref-type="fig"}A), such that spleen weight in the Tg mice was markedly increased compared with that in WT mice ([Figure 5](#F5){ref-type="fig"}B). We therefore examined splenic cell populations by FACS analysis using antibodies against cell lineage-specific markers. [Figure 5](#F5){ref-type="fig"}(C) summarizes the results. Essentially, there were no appreciable differences in populations of effector T-cells, including CD4^+^ and CD8^+^ T-cells, various differential stages of B-cells, including CD21^+^, sIgM^+^, sIgD^+^ and CD23^+^ cells, and NK (natural killer) (NK1.1^+^) cells ([Figure 5](#F5){ref-type="fig"}C). In contrast, splenic Gr-1^+^ neutrophils, CD11b^+^ monocytes/macrophages and CD11c^+^ dendritic cells were increased \>2-fold in *Pla2g3*-Tg mice relative to WT mice ([Figure 5](#F5){ref-type="fig"}C). Therefore PLA2G3 overexpression preferentially affects the haemopoietic, rather than the lymphocytic, lineages of splenic cells at this stage.

![Altered splenic cell populations in *Pla2g3*-Tg mice\
(**A**) Splenomegaly of 5-month-old *Pla2g3*-Tg mice (III-Tg) in comparison with that of age-matched WT mice. (**B**) Spleen weight per body weight was nearly doubled in *Pla2g3*-Tg mice (III-Tg) relative to that in WT mice (means±S.D., *n*=4, \**P*\<0.05). (**C**) Distribution of splenic cell populations in WT and *Pla2g3*-Tg (III-Tg) mice. FACS was performed with antibodies for CD3 (T-cells), CD45R (B-cells), NK1.1 (NK cells), Gr-1 (granulocytes), CD11c (dendritic cells) and CD11b (monocytes/macrophages) (left-hand panel). T-cell lineages were sorted further with antibodies for CD4 and CD8, and B-cell lineages were sorted with antibodies for CD21, CD23, sIgM and sIgD (right-hand panel). Values are means±S.D. for three independent experiments (\**P*\<0.05).](bic657i005){#F5}

In agreement with the above observations, numbers of circulating granulocytes and monocytes were increased in 9--10-month-old *Pla2g3*-Tg mice compared with WT mice, whereas they were similar in young adults (2--3-months-old) of both genotypes ([Figure 6](#F6){ref-type="fig"}A, panels a and b). The number of circulating lymphocytes tended to increase in young, rather than aged, PLA2G3 mice relative to WT mice, although this difference was not statistically significant ([Figure 6](#F6){ref-type="fig"}A, panel c). Platelet and erythrocyte counts were unaffected in *Pla2g3*-Tg mice throughout the experimental periods ([Figure 6](#F6){ref-type="fig"}A, panels d and e). Likewise, haemoglobin levels and haematocrit values in the blood were indistinguishable between the genotypes ([Figure 6](#F6){ref-type="fig"}B). In addition, serum IgG~1~ was increased \>7-fold in aged *Pla2g3*-Tg mice relative to WT mice, whereas serum IgM, IgG~2a~ and IgE levels were unchanged ([Figure 6](#F6){ref-type="fig"}C).

![Changes in circulating cell populations and serum immunoglobulin levels in *Pla2g3*-Tg mice\
The numbers of circulating granulocytes, monocytes, lymphocytes, platelets and erythrocytes (**A**), as well as haemoglobin and haematocrit values (**B**), in young (11--13-week-old) and aged (38--41-week-old) WT and *Pla2g3*-Tg (Tg) mice were evaluated using VetScan HM (means±S.D., *n*=4--12, \**P*\<0.05). (**C**) Serum concentrations of IgG1, IgM, IgG2a and IgM were determined by sandwich ELISA (means±S.D., *n*=3, \**P*\<0.05). (**D**) Peritoneal macrophages from *Pla2g3*-Tg (III-Tg) and WT mice were cultured for the indicated periods in culture medium (left-hand panel) or for 24 h in medium with (+) or without (−)1 μg/ml LPS (right-hand panel). The supernatants were taken for PGE~2~ enzyme immune assay. A representative result of two reproducible results (panel a) and means±S.E.M. for four experiments (panel b) are shown. \**P*\<0.05 compared with replicate WT cells. (**E**) Peritoneal macrophages from *Pla2g3*-Tg (III-Tg) and WT mice were cultured for 24 h in culture medium with (+) or without (−) LPS (right-hand panel). The supernatants were taken for ELISA for IL-6 (means±S.E.M., *n*=4, \**P*\<0.05 compared with replicate WT cells). Inset, IL-6 production by the cells cultured in the absence of LPS is magnified.](bic657i006){#F6}

To examine further the potential contribution of PLA2G3 to the inflammatory response, we examined PGE~2~ generation *ex vivo* by peritoneal macrophages derived from *Pla2g3*-Tg and WT mice. Spontaneous production of PGE~2~ over 12 h of culture was higher in macrophages from Tg mice than in those from control mice ([Figure 6](#F6){ref-type="fig"}D, panel a). After stimulation of macrophages with LPS (lipopolysaccharide) for 24 h, WT-derived cells showed vigorous production of PGE~2~, which was further augmented 3-fold in replicate Tg-derived cells ([Figure 6](#F6){ref-type="fig"}D, panel b). These *ex vivo* experiments agree with our previous observations that PLA2G3 has the capacity to augment arachidonic acid metabolism in various cultured cells when overexpressed \[[@B14],[@B15]\]. Moreover, LPS-stimulated *Pla2g3*-Tg macrophages produced more IL-6 than did replicate WT cells ([Figure 6](#F6){ref-type="fig"}E). Even in the absence of LPS stimulation, IL-6 release was significantly increased in macrophages of *Pla2g3*-Tg mice compared with those of control mice ([Figure 6](#F6){ref-type="fig"}E, inset). Thus overexpression of PLA2G3 enhances the inflammatory response in macrophages.

DISCUSSION
==========

Because of the ability of PLA~2~ enzymes to release arachidonic acid (a precursor of various lipid mediators such as prostaglandins and leukotrienes) and lysophospholipids such as lysophosphatidic acid and 1-*O*-alkyl lysophosphatidylcholine \[a precursor of PAF (platelet-activating factor)\] from membrane phospholipids, it has long been thought that these enzymes participate in a wide variety of diseases, such as inflammation, atherosclerosis and cancer, in which lipid mediators play pivotal roles. Gene ablation of group IVA cPLA~2~α, a stimulus-coupled intracellular PLA~2~ that is regulated by phosphorylation and Ca^2+^-dependent membrane translocation, has established the importance of this arachidonate-selective enzyme in the production of eicosanoids and PAF in most, if not all, cells and tissues \[[@B19]\]. Although several sPLA~2~s are capable of releasing arachidonic acid from isolated or cultured cells *in vitro* \[[@B1]--[@B3]\], the pathophysiological relevance of this event *in vivo* has remained elusive. Although PLA2G2A is a prototypic inflammatory PLA~2~ whose expression is markedly elevated during various inflammatory states in humans and experimental animals (except in mice, in which the *Pla2g2a* gene is naturally disrupted (e.g. C57BL/6) or expressed only in the intestine (e.g. BALB/c \[[@B20]\]), its contribution to lipid mediator production *in vivo* has not yet been proven conclusively. Tg mice overexpressing human or mouse PLA2G2A do not show any sign of inflammation, although they display a notable alopecic phenotype with hyperkeratosis \[[@B4],[@B21]\]. Furthermore, animals overexpressing the mouse enzyme are sensitive to two-stage chemical carcinogenesis, with development of a higher number of skin papillomas and then of carcinomas than in replicate control mice \[[@B21]\]. Rather, the main function of PLA2G2A is now recognized to be protection of the host from microbial invasion by degrading bacterial membranes, in which phosphatidylethanolamine and phosphatidylglycerol, two preferred substrates for PLA2G2A, are major phospholipid components \[[@B9]\]. PLA2G5 and PLA2G10 have much higher capacity to interact with PC-rich outer plasma membranes to release arachidonic acid than does PLA2G2A \[[@B22],[@B23]\]. The involvement of both PLA2G5 and PLA2G10 in inflammation and associated lipid-mediator production, such as zymosan-induced peritonitis \[[@B5]\], methacholine-induced airway hypersensitivity \[[@B6]\], T~H2~-biased asthmatic response \[[@B7]\] and ischaemia/reperfusion-induced myocardial damage \[[@B8]\], has been demonstrated in studies using *Pla2g5*-null or *Pla2g10*-null mice, even though it remains uncertain whether arachidonic acid is supplied directly through the membrane-hydrolytic action of these sPLA~2~s or indirectly through the activation of cPLA~2~α or other enzymes in those situations.

In the present study, we found that Tg mice carrying the transgene for human PLA2G3, another sPLA~2~ that is capable of efficient hydrolysis of PC-rich membranes \[[@B14],[@B15]\], frequently developed inflammation as they aged. This is, to our knowledge, the first demonstration that Tg overexpression of a particular form of sPLA~2~ induces inflammation in the skin. By 1 year of age, *Pla2g3*-Tg mice displayed dermatitis associated with acanthosis, hyperkeratosis, parakeratosis, sebaceous gland hyperplasia, erosion and ulcer, with massive dermal infiltration of inflammatory cells, such as neutrophils and macrophages, and elevated expression of pro-inflammatory cytokines and chemokines, such as IL-1β, IL-6, TNFα and CCL2 ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). A moderate but significant expression of IL-4, but not IFNγ and IL-12, suggests a tendency to a T~H2~ response rather than a T~H1~ response. The affected skin in *Pla2g3*-Tg mice is histologically similar to that of patients with atopic dermatitis, but is distinct from that of *Pla2g2a*-Tg mice \[[@B4]\], which develop alopecia and epidermal hyperplasia in the absence of inflammation. Therefore the mechanisms underlying the skin phenotypes induced by PLA2G3 (with inflammation) and PLA2G2A (without inflammation) may not be identical.

PGE~2~, as well as its biosynthetic enzymes (COX-2 and mPGES-1), was markedly increased in skin lesions of *Pla2g3*-Tg mice ([Figure 3](#F3){ref-type="fig"}), indicating that PLA2G3 facilitates arachidonic acid metabolism. At present, it is unclear whether the elevation of this arachidonate metabolite reflects increased PLA2G3-directed membrane hydrolysis or a secondary effect involving the activation of other PLA~2~s (such as cPLA~2~α) in infiltrating leucocytes, keratinocytes or other cell types in response to elevated levels of pro-inflammatory cytokines/chemokines. Nevertheless, peritoneal macrophages from *Pla2g3*-Tg mice produced more PGE~2~ and IL-6 than did those from control mice, particularly after stimulation with LPS ([Figures 6](#F6){ref-type="fig"}D and [6](#F6){ref-type="fig"}E), an observation that accords with studies showing that PLA2G3 can promote arachidonic acid release in multiple types of cultured cells \[[@B14],[@B15]\] and that the skin lesions in *Pla2g3*-Tg mice showed elevated levels of pro-inflammatory cytokines and PGE~2~ with a concomitant infiltration of macrophages ([Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). The inflammatory signs are not restricted to the skin, but are also seen in other tissues including salivary gland, lung, liver, spleen and even blood ([Figures 4--6](#F4){ref-type="fig"}). In this context, a likely explanation for the inflammatory phenotype is that sustained, albeit moderate, increases in levels of lipid mediators within the affected tissues might lead to a gradual onset of inflammation in *Pla2g3*-Tg mice. For instance, PGE~2~, through its receptor EP2, promotes epidermal hyperplasia and dermal macrophage infiltration \[[@B23a]\], which are reminiscent of *Pla2g3*-Tg skin ([Figure 1](#F1){ref-type="fig"}). In accordance, episodes of infection with environmental micro-organisms through cutaneous lesions, particularly wounded areas as a result of increasing scratching behaviour, might facilitate the expansion, migration and activation of neutrophils and macrophages, thereby leading to exacerbation of local and systemic inflammatory responses.

It is intriguing to note that the skin inflammation in *Pla2g3*-Tg mice was accompanied by increased expression of PLA2G5 and PLA2G2D ([Figure 3](#F3){ref-type="fig"}C). This suggests that these two sPLA~2~s are associated with inflammation, either through transcriptional up-regulation in resident cells or through infiltration of inflammatory cells in which these sPLA~2~s are expressed. Both situations might be applied to PLA2G5, since this enzyme is known to be expressed in macrophages \[[@B24]\], a cell population which is increased in *Pla2g3*-Tg skin, and since its expression has been reported to be induced in cytokine-stimulated macrophage-like cells \[[@B25]\] and keratinocytes \[[@B26]\]. Increased expression of PLA2G2D has been reported in a mouse model of atopic dermatitis \[[@B27]\]. On the other hand, PLA2G2E and PLA2G2F, as well as endogenous PLA2G3, were consistently detected in WT and *Pla2g3*-Tg skin ([Figure 3](#F3){ref-type="fig"}C), suggesting that these sPLA~2~ enzymes are constitutively expressed in certain resident cells, rather than in infiltrating leucocytes, within the skin niche. Importantly, judging from the intensity of RT--PCR bands, the expression of endogenous mouse PLA2G3 in WT skin is similar to that of human PLA2G3 overexpressed in Tg skin ([Figure 3](#F3){ref-type="fig"}C), suggesting a potential contribution of this enzyme to skin inflammation under certain pathological conditions. In contrast with previous reports describing the expression of PLA2G10 in newborn mouse skin \[[@B28]\], we failed to detect its transcript in the skin of either WT or *Pla2g3*-Tg mice ([Figure 3](#F3){ref-type="fig"}C); this might be due to the difference in ages or strains examined (neonatal NMRI mice compared with aged C57BL/6 mice).

As we have reported recently, alterations in plasma lipoproteins \[a decrease in HDL (high-density lipoprotein) and an increase in atherogenic LDL (low-density lipoprotein)\] occur in *Pla2g3*-Tg mice \[[@B16]\]. Interestingly, a potential linkage between altered lipoprotein levels and chronic inflammatory diseases has been proposed \[[@B29]--[@B32]\]. Mice deficient in LDL receptor and apolipoprotein A-I, in which plasma cholesterol levels were markedly altered, suffered from increasingly severe ulcerated cutaneous inflammation, and, in these mice, cholesterol accumulation in the skin was associated with macrophage infiltration and was accompanied by increases in TNFα and COX-2 \[[@B29],[@B30]\]. Tg overexpression of apolipoprotein C1 decreased lipids in the sebaceous gland, epidermis and subcutaneous adipose tissue, leading to dry and scaly skin with loss of hair, epidermal hyperplasia, hyperkeratosis and atrophic sebaceous glands lacking sebum \[[@B31]\]. An increase in circulating HDL led to a significant inhibition of basal and IL-1α-induced E-selectin expression, suggesting the potential anti-inflammatory action of HDL \[[@B32]\]. These observations raise the possibility that systemic alterations in circulating LDL and HDL in *Pla2g3*-Tg mice \[[@B16]\] might be responsible, at least in part, for the acceleration of inflammation. Interestingly, *Pla2g2a*-Tg mice, which develop skin abnormalities \[[@B4]\], also show reduced plasma HDL levels \[[@B10]\], and disturbance of systemic lipid homoeostasis has often been linked with skin abnormalities in various mouse models and even in human diseases \[[@B33]--[@B35]\]. Therefore potential causal relationships between altered systemic lipoprotein levels and skin abnormalities in mouse models with Tg overexpression of particular forms of sPLA~2~ should be taken into account. Moreover, given the recent recognition that atherosclerosis is a form of chronic inflammation in the vascular wall \[[@B36]\], the atherosclerotic \[[@B16]\] and inflammatory (the present study) phenotypes of *Pla2g3*-Tg mice may be interrelated.

Endogenous *PLA2G3* mRNA in humans is detected in several tissues such as kidney, heart, liver and skeletal muscle \[[@B13]\], and immunoreactive PLA2G3 protein is localized in microvascular endothelial cells, macrophages, peripheral neuronal fibres, atherosclerotic plaques and tumour cells in tissues from human subjects with diseases (e.g. inflammation, ischaemia, atherosclerosis and cancer) \[[@B15],[@B16],[@B37],[@B38]\]. In mice, endogenous *Pla2g3* mRNA is detected at trace levels in various tissues (H. Sato, Y. Taketomi and M. Murakami, unpublished work), among which the nervous system (e.g. brain, spinal cord and dorsal root ganglion) shows the highest expression \[[@B37]\]. Essentially, unlike PLA2G2A, whose tissue expression profiles differ considerably between human and mouse \[[@B20]\], it appears that human and mouse PLA2G3 orthologues (∼82% homology in their core S domain) display a similar, if not entirely identical, tissue distribution pattern. In cell culture systems, forcible expression or exogenous addition of human PLA2G3 facilitates the axonal growth and survival of neuronal cells, proliferation of colorectal cancer cells, maturation of dendritic cells, migration of endothelial cells and inhibition of viral infection, whereas introduction of PLA2G3-directed small interfering RNA partially suppresses some of these events, probably through altering the cellular levels of lysophospholipids or eicosanoids \[[@B14],[@B15],[@B37],[@B39],[@B40]\]. Detection of endogenous PLA2G3 in mouse skin ([Figure 3](#F3){ref-type="fig"}C) raises the intriguing possibility that this unique type of sPLA~2~ might function in skin biology. Besides the effect of PLA2G3 on lipid mediator generation, PLA2G3 might be coupled with a particular signalling pathway through interacting with the putative N-type sPLA~2~ receptor, to which bee venom PLA~2~ (a PLA2G3 homologue) is known to bind as a ligand \[[@B41]\]. It will be necessary to reconcile the precise *in vivo* actions, expression and dynamics of PLA2G3 by conducting studies with *Pla2g3* gene-disrupted mice or with PLA2G3-specific inhibitors. Nevertheless, despite the limitations of Tg overexpression strategies, the mouse model described in the present paper might be useful to uncover the molecular actions of sPLA~2~ family enzymes, including tissue-specific target substrates and their metabolites, during the process of inflammation or other related diseases. Furthermore, this mouse line has potential for the screening of novel anti-inflammatory agents aiming at inhibiting sPLA~2~-mediated phospholipid hydrolysis.
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